Corporate News
Directorate Change
10 July 2025
CNSL (AIM:CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, is pleased to announce that it has appointed Ajay Patel to the Board as Chief Financial Officer ("CFO") and Executive Director with immediate effect.
Ajay has over 30 year's experience in finance, having graduated from University College London, trained at PWC, and spending 14 years at Tesco in a range of senior finance roles. He has significant CFO and Company secretary exposure to growing businesses in retail, e-commerce, logistics, wholesaling, education and charities.
Carolyn Rand, Chair, said: "As a Board, I am delighted to welcome someone with Ajay's experience into our business to work alongside our CEO to help drive the business forward and deliver our strategy. This is evidence of our commitment to strengthening our Board with individuals who bring a wealth of experience and strategic insight into the organisation. I am sure, together with James we have a very strong Executive team who will play a key part in our future success".
James Cooper, Chief Executive Officer, said: "I am very pleased to welcome Ajay to our Board and look forward to working closely with him to achieve our strategic objectives. Ajay has significant experience and I am very excited at how this can help drive our growth agenda as well as develop our people and leadership in the organisation."
Contacts:
Cambridge Nutritional Sciences Plc | |
James Cooper, Chief Executive Officer | |
Cavendish Capital Markets Limited | Tel: 020 7220 0500 |
Geoff Nash / Edward Whiley (Corporate Finance) | |
Nigel Birks / Harriet Ward (ECM) |
About Cambridge Nutritional Sciences Plc
Cambridge Nutritional Sciences Plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.
The following disclosures are made in accordance with Schedule 2(g) of the AIM Rules for Companies:
Ajay Patel, aged 60, does not currently hold any ordinary shares in the Company. Ajay also holds no options in the Company.
Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.
Current Directorships and Partnerships | Previous Directorships and Partnerships (held in the past five years) |
A Tunnel Wood Limited | Entoria Winecellars Limited |
TBP Realisations Limited | |
Tengo (Holdings) Limited | |
M & G Presents Limited | |
Tengo Limited | |
TBP Realisations Group Limited | |
Sonderwell Bidco Limited | |
Better Healthcare Services Limited | |
Enviva Care Limited | |
Invent Health Limited | |
Enviva Complex Care Limited | |
Libertatem Healthcare Group Limited | |
Sonderwell Midco Limited | |
Sonderwell Finco Limited | |
BECC: Bespoke Complex Care Support Limited | |
Arrow Support Limited | |
Diversity Care Solutions Limited | |
Libertatem Healthcare Holdings Ltd | |
Sonderwell Topco limited | |
Sekforde Drinks Limited | |
Great Western Wine Company Limited (The) | |
Coe of Ilford Limited | |
Gin Foundry Limited | |
Winecellars Limited | |
Entoria Winecellars Limited | |
Entoria Group Limited | |
Entoria Holdings Limited |
TBP Realisations Limited (formerly The Book People Limited) appointed administrators on 16 December 2019. PWC were appointed originally to affect an accelerated M&A process with parallel contingency planning, but no buyer was secured. The final administrator's progress report reported that secured creditor Endless LLP had received £11.10 million while unsecured creditors received 3.69% totalling £541,000.00.
Tengo (Holdings) Limited, M & G Presents Limited, Tengo Limited and TBP Realisations Group Limited all entered Creditors Voluntary Liquidation on 13 March 2020. No realisations were made from the liquidations.
Squeaky Gate entered Creditor's Voluntary Liquidation on 14 April 2014. Non-preferential unsecured creditors claimed £319,373.1. No dividend was declared to these unsecured creditors.
Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.
